Why Is MODERNA INC (MRNA) Stock Moving Today?

Why MRNA stock is moving today

Moderna Inc (MRNA) shares are moving sharply higher today, rising over 13% in a volatile session marked by a large intraday swing. The stock opened with a 3.1% gap up and reached a high of $159.47 before pulling back to $139.75 in late trading. The rally appears to be driven by broader biotech momentum and renewed optimism around the company’s mRNA-based cancer vaccine research, despite a recent downgrade from JPMorgan.

What Happened

Moderna shares surged amid a broader biotech sector rally, fueled in part by recent developments in mRNA cancer therapies. The stock climbed to a session high of $159.47, a level that would have marked a new 52-week high, before retreating. This movement occurred despite JPMorgan analyst Jessica Fye maintaining her Sell rating on the stock. The biotech sector as a whole is responding to positive momentum in mRNA-based treatments, with Moderna and Merck’s intismeran autogene trial results contributing to the broader market narrative. However, Leerink Partners has warned that the success of this one drug does not guarantee similar outcomes for other developers in the space.

What The Data Shows

The stock has moved +137.2% over the last eight sessions, from $63.59 to $150.85, indicating a strong short-term price trend. Today’s session has seen unusually high volume of 54.8 million shares, or 5.9 times the 3-month average. Options activity has also been notable, with $301.2 million in call premiums compared to $200.7 million in puts. The largest single options print totaled $164.7 million. In terms of fundamentals, Moderna remains unprofitable, with a trailing twelve-month revenue decline of 27.6% and a net margin of -141.4%. The stock has also seen recent insider selling, with four sales totaling $35.2 million in the last 90 days.

What To Watch

The stock is currently trading near its 52-week high of $176.66. With unusual options activity and a sharp price move, investors may want to monitor the next earnings report or any further developments in Moderna’s cancer vaccine trials.